戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eisseria meningitidis, Escherichia coli, and Pseudomonas aeruginosa infection).
2  one such metabolite that is secreted during Pseudomonas aeruginosa infection.
3 l genes were also found to be induced during Pseudomonas aeruginosa infection.
4 ter, was validated in a murine model of lung Pseudomonas aeruginosa infection.
5 ling in C57BL/6 mouse corneas in response to Pseudomonas aeruginosa infection.
6  (TLR6/1) and have reduced responses to live Pseudomonas aeruginosa infection.
7 degeneration mediated by oxidative stress or Pseudomonas aeruginosa infection.
8  the eye from pathogenic Candida albicans or Pseudomonas aeruginosa infection.
9 t poly(I:C), improved the host response to a Pseudomonas aeruginosa infection.
10 rse outcomes, particularly in the setting of Pseudomonas aeruginosa infection.
11  (KO) mice with aerosolized LPS (100 mug) or Pseudomonas aeruginosa infection.
12 se is critical in the prognosis of pulmonary Pseudomonas aeruginosa infection.
13 eased in splenic natural killer cells during Pseudomonas aeruginosa infection.
14 f CF BAL fluid samples from patients without Pseudomonas aeruginosa infection.
15 ssociated with refractory CRS and persistent Pseudomonas aeruginosa infection.
16 ppaB signalling upon Gram-negative bacterium Pseudomonas aeruginosa infection.
17 cterial clearance and survival of mice after Pseudomonas aeruginosa infection.
18 's tautomerase activity in a murine model of Pseudomonas aeruginosa infection.
19 ctors associated with both chronic and acute Pseudomonas aeruginosa infection.
20 xia succumbed to death during recovery after Pseudomonas aeruginosa infection.
21 rneal perforation in C57BL/6 (B6) mice after Pseudomonas aeruginosa infection.
22  interactions in response to acute pulmonary Pseudomonas aeruginosa infection.
23 tients with cystic fibrosis who have chronic Pseudomonas aeruginosa infection.
24 tibility of cystic fibrosis (CF) patients to Pseudomonas aeruginosa infection.
25 ramycin in patients with cystic fibrosis and Pseudomonas aeruginosa infection.
26 three or more exacerbations per year without Pseudomonas aeruginosa infection.
27 adult Swiss (HSD:ICR) mice is restored after Pseudomonas aeruginosa infection.
28 ronounced hypersusceptibility (80 to 90%) to Pseudomonas aeruginosa infection.
29 se models of intraperitoneal and respiratory Pseudomonas aeruginosa infection.
30 tion in response to an experimental model of Pseudomonas aeruginosa infection.
31 antibiotic response in patients with chronic Pseudomonas aeruginosa infection.
32 , thereby contributing to the persistence of Pseudomonas aeruginosa infections.
33 sponse of cystic fibrosis and sensitivity to Pseudomonas aeruginosa infections.
34 e challenged two strains of mice with lethal Pseudomonas aeruginosa infection 3 weeks after immunizat
35 ted (68 vs. 77%, p < 0.001), higher rates of Pseudomonas aeruginosa infection (71 vs. 65%, p < 0.01),
36                            Here we show that Pseudomonas aeruginosa infection activates mouse tuft ce
37               We investigated an outbreak of Pseudomonas aeruginosa infections after bronchoscopic pr
38 choice in the setting of multidrug-resistant Pseudomonas aeruginosa infections, although high doses o
39 fection among HIV-negative patients and with Pseudomonas aeruginosa infections among HIV-positive pat
40 nitial point of host-pathogen interaction in Pseudomonas aeruginosa infection, an important pathogen
41 e the in vivo functions of SPLUNC1 following Pseudomonas aeruginosa infection and to elucidate the un
42                                              Pseudomonas aeruginosa infections and biofilms have been
43  of CF lung disease while adjusting for age, Pseudomonas aeruginosa infection, and cystic fibrosis tr
44 urine listeriosis model, the neutropenic rat Pseudomonas aeruginosa infection, and the mouse cecal li
45                                      Chronic Pseudomonas aeruginosa infections are characterized by b
46                                              Pseudomonas aeruginosa infections are increasingly multi
47  resistance during multidrug resistant (MDR)-Pseudomonas aeruginosa infections are limited.
48 rventions to treat multidrug-resistant (MDR) Pseudomonas aeruginosa infections are severely limited a
49 esponse (within 24 hours) to an experimental Pseudomonas aeruginosa infection between vitamin A defic
50  induced in mouse macrophages in response to Pseudomonas aeruginosa infection both in vivo and by iso
51                          Here, we found that Pseudomonas aeruginosa infection, but not other common b
52 r cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection, but there has not been
53 esults show that B-glucan protects mice from Pseudomonas aeruginosa infection by augmenting recruitme
54                                              Pseudomonas aeruginosa infections can be virtually impos
55                                              Pseudomonas aeruginosa infection category in the year be
56 scribe 2 cases of extensively drug-resistant Pseudomonas aeruginosa infection caused by a strain of p
57                                    Recurrent Pseudomonas aeruginosa infections coupled with robust, d
58                 Furthermore, analysis of all Pseudomonas aeruginosa infections demonstrated no signif
59 characterize clusters of genetically-related Pseudomonas aeruginosa infections during a 24-month peri
60                                              Pseudomonas aeruginosa infection elicits the production
61 y observed in clinical isolates from chronic Pseudomonas aeruginosa infections, enables bacteria to e
62 ithelium is seriously damaged upon pulmonary Pseudomonas aeruginosa infection, especially in cystic f
63 p=0.037) when adjusted for sex, BMI, chronic Pseudomonas aeruginosa infection, FEV1/FVC (forced vital
64 an injury and improved outcomes of secondary Pseudomonas aeruginosa infections following caecal ligat
65                                              Pseudomonas aeruginosa infections frequently involve bio
66                                              Pseudomonas aeruginosa infections generally persist desp
67                                              Pseudomonas aeruginosa infection has been demonstrated t
68                            Susceptibility to Pseudomonas aeruginosa infection has been linked to the
69     Chem-8dK showed in vivo efficacy against Pseudomonas aeruginosa infection in BALB/c mice and inhi
70 ns cells were induced into the cornea before Pseudomonas aeruginosa infection in BALB/c mice that are
71                           This suggests that Pseudomonas aeruginosa infection in CF reflects biofilm
72 ng protein (BPI) is strongly associated with Pseudomonas aeruginosa infection in cystic fibrosis (CF)
73                      One of the hallmarks of Pseudomonas aeruginosa infection in cystic fibrosis (CF)
74 udy was to determine whether PLUNC can limit Pseudomonas aeruginosa infection in mice.
75                                      Chronic Pseudomonas aeruginosa infection in persons with CF is a
76 tor mutation to the onset and persistence of Pseudomonas aeruginosa infection in the airways, and her
77 his study to track the IFN-gamma response to Pseudomonas aeruginosa infection in the lung over time i
78 tudy, S5-PmnH, exhibits excellent control of Pseudomonas aeruginosa infection in validated murine ker
79 er Phase II clinical trials to treat chronic Pseudomonas aeruginosa infections in cystic fibrosis pat
80 w immunogenic antigens that diagnose initial Pseudomonas aeruginosa infections in patients with cysti
81   While standard PEx treatment for PwCF with Pseudomonas aeruginosa infection includes two IV antipse
82 promoter exhibited an elevated resistance to Pseudomonas aeruginosa infection, indicating that these
83                             LPS treatment or Pseudomonas aeruginosa infection induces miR-301b expres
84                                              Pseudomonas aeruginosa infection is a clinically relevan
85                             In burn patients Pseudomonas aeruginosa infection is a major cause of mor
86                                   Rationale: Pseudomonas aeruginosa infection is associated with wors
87  mucociliary clearance, and establishment of Pseudomonas aeruginosa infection is described.
88                             Although chronic Pseudomonas aeruginosa infection is the major cause of m
89  A novel immunochemical approach to diagnose Pseudomonas aeruginosa infections is reported, which is
90 ic endobronchiolitis compounded by recurring Pseudomonas aeruginosa infections is the major cause of
91                                              Pseudomonas aeruginosa infection liberates transmissible
92                                      Chronic Pseudomonas aeruginosa infection occurs in 75-90% of pat
93 cornea keratitis model was modified to study Pseudomonas aeruginosa infection of healing corneal epit
94 tactic gradients, and migrate in response to Pseudomonas aeruginosa infection of primary ALI barriers
95                         Here we investigated Pseudomonas aeruginosa infections of the cornea in Lum(-
96 OR, 1.08; P = 3.4 x 10-10), and intermittent Pseudomonas aeruginosa infection (OR, 1.51; P = .004) we
97 was not altered by genotype, age, gender, or Pseudomonas aeruginosa infection, oral steroid treatment
98  the incidence or severity of Klebsiella and Pseudomonas aeruginosa infections, patients admitted to
99  Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa infections post-ASP.
100  Splenic natural killer cells activated upon Pseudomonas aeruginosa infection produced interferon-gam
101                      Prevention of pulmonary Pseudomonas aeruginosa infections represents a critical
102       With the rise of multidrug resistance, Pseudomonas aeruginosa infections require alternative th
103               In a mouse model of pneumonia, Pseudomonas aeruginosa infection results in rapid vILC3
104                                       During Pseudomonas aeruginosa infection, SCF (FBXL2) targets th
105 n cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection, the underlying mechani
106 nts who were ExBF >/=2 mo, and the number of Pseudomonas aeruginosa infections through the age of 2 y
107 leus, histamine blocker use, and respiratory Pseudomonas aeruginosa infection were associated with lo
108        Results for patients with and without Pseudomonas aeruginosa infection were compared.
109  bacterial outgrowth from cells subjected to Pseudomonas aeruginosa infection were used to determine
110 tactic stimuli (a CXCL1 chemokine and a live Pseudomonas aeruginosa infection) were administered 48 h
111 e synthesis and cell viability in a model of Pseudomonas aeruginosa infection where Ca(2+) concentrat
112  epithelial cells and restored resistance to Pseudomonas aeruginosa infections, which is one of the m
113 omplicated by a life-threatening chronic MDR Pseudomonas aeruginosa infection, who is treated success

 
Page Top